medigraphic.com
ISSN 0016-3813 (Print)

2002, Number S1

<< Back Next >>

Gac Med Mex 2002; 138 (S1)

Advances in Thrombosis

I. Risk Stratification in Venous Thromboembolytic Disease in Surgical Patients and Physicians.
II. Pathogenic Mechanisms of Antiphospholipid Antibody Syndrome.
III. Fibrinolysis and Cancer.

Martínez-Murillo C, Majluf-Cruz A, Ruiz-Argüelles G, González-Llaven J

Language: Spanish
References: 86
Page: 68-77
PDF size: 77.23 Kb.


Text Extraction

No abstract


REFERENCES

  1. Caprini JA, Arcelus JI, Reyna JJ. Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. Semin. Hematol. 2001;38:12-19.

  2. Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Haemost 1999;25:173-182.

  3. Hull RD, Pineo GF. Clinical features of deep vein trombosis. In: Hull RD, Raskob GE, Pineo GF, editors. VTE: an evidence-based atlas. Armonk, NY. USA: Futura Publishing; 1996:87-91.

  4. Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7.

  5. Bratzler DW, Raskob GE, Murray CK, et al. Underuse of VTE prophylaxis for general surgery patients: Physicians' practices in the community hospital setting. Arch Intern Med 1998;158:1909-1912.

  6. Gillies TE, Ruckley CV, Nixon SJ. Still missing the boat with fatal pulmonary embolism. Br J Surg 1996;83:1394-1395.

  7. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr, Wheeler HB. Prevention of venous thromboembolism. Chest 2001;119:S132-S175.

  8. Anderson FA Jr, Wheleer HB, Goldberg RJ, et al. Prospective study of the impact of continuing medical education and quality assurance programs on use of prophylaxis for VTE. Arch Intern Med 1994;154:669-677.

  9. Flordal PA, Bergqvist D, Burmark U-S, et al. Risk factors for major thromboembolism and bleeding tendency after elective general surgical operations. Eur J Surg 1996;162:783-789.

  10. Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of VTE in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000;83:14-19.

  11. Alarcón-Segovia D. Pathogenetic potential of antiphospholipid antibodies. Rheumatol 1988;15:890-893.

  12. Alarcón-Segovia D, Delezé M. Oria CV, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine 1989;68:353-365.

  13. Alarcón-Segovia D, Sánchez-Guerrero J. Primary antiphospholipid syndrome. J Rheumatol 1989;16:482-488.

  14. Alarcón-Segovia D, Cardiel M, Reyes E. Antiphospholipid arterial vasculopathy. J Rheumatol 1989;16:762-767.

  15. Alarcón-Segovia D. Pathogenetic potential of antiphospholipid antibodies. J Rheumatol 1988;15:890-893.

  16. Alarcón-Segovia D, Sánchez-Guerrero J. Correction of thrombocytopenia with small dose aspirin in the primary anti-phospholipid syndrome. J Rheumatol 1989;16:1359-1361.

  17. Alarcón-Segovia D, Cabral AR. Antiphospholipid antibodies- where do they come from? Where do they go? J Rheumatol 1994;21:982-989.

  18. Alarcón-Segovia D, Ruiz-Argüelles GJ, Garcés-Eisele J, Ruiz-Argüelles A.: Inherited activated protein C resistance in a patient with familial antiphospholipid syndrome. J Rheumatol 1996;23: 2162-5.

  19. Alarcón-Segovia D, Sánchez-Guerrero J. Primary antiphospholipid syndrome. J Rheumatol 1989;16:482.

  20. Anglés-Cano E, Sultan Y, Clauvel JP. Predisposing factors to thrombosis in systemic lupus erythematosus: possible relation to andothelial cell damage. J Lab Clin Med 1979;94:313-323.

  21. Asherson RA, Khamashta MA, Ordi-Ros J, et al. The “primary” antiphospholipid syndrome: major clinical and serological features. Medicine 1989;68:366-374.

  22. Borrel M, Fontcuberta J, Muñiz E, et al. Fibrinolytic activity and other coagulation proteins in patients with the lupus anticoagulant. Thromb Haemost 1987; 58:393 (Abstract).

  23. Cabiedes J, Cabral AR, Alarcón-Segovia D. Clinical manifestations of the antiphospholipid syndrome in systemic lupus erythematosus patients associate more strongly with anti-beta 2 glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 1995;49:109.

  24. Carreras LO, Vermylen JG. Lupus anticoagulant and thrombosis. Possible role of inhibition of prostacyclin formation. Thromb Haemost 1982;48:38-40.

  25. Carreras LO, Defreyn G, Machin SL. Arterial thrombosis, intrauterine death and lupus anticoagulant. Detection of an immunoglobulin interfering with prostacyclin formation. Lancet 1981;1:244-246

  26. Conley CL, Hartmann RC. A hemorrhagic disorders caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 1952;31:621-627

  27. Deegan MJ. Anti-phospholipid antibodies. Am J Clin Pathol 1992; 98:390-391.

  28. Exner T, McRea J. Studies on the relationship between antiphospholipid antibodies and the lupus anticoagulant. Blood Coagul Fibrinolysis 1990;1:17-21.

  29. Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. In Spaet T, editors. Progress in hemostasis and thrombosis. Vol. 1. New York: Grunne & Stratton;1972. p. 775-92.

  30. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda, Vriesman PJC, Barbui T, Zwaal RFA, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544-1547.

  31. Goodnight SH. Antiphospholipid antibodies and trhombosis. Curr Opini Hematol 1994;1:354-361.

  32. Green D, Hougie C, Kazmier F,J et al. Report of the Working Party on AcquiredInhibitors of Coagulation: Studies of the Lupus Anticuagulant. Thromb Haemost 1983;49:144-150.

  33. Harris EN. Antiphospholipid antibodies. Br J Haematol 1990;74:1-9.

  34. Harris EN, Gharavi AE, Patel SP, Hughes GRV. Evaluation of the anticardiolipin antibody test: Report on an International Workshop, 4 ApriL 1986. Clin Exper Immunol 1987;68:215-22.

  35. Key NS. Toward an understanding of the pathophysiologic mechanism of thrombosis in the antiphospholipid syndrome. J Lab Clin Med 1995;125:16

  36. Khamashta MA, Cervera R, Asherson RA, Font J, Gil A, Coltart DJ, Vázquez JJ, Pare C, Ingelmo M, Oliver S, Hughesr GRV. Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet 1990; 335: 1541-1544.

  37. Love PE, Santoro SA. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med 1990;112:682-689.

  38. Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990;76:101-107.

  39. Matsuda J, Gohchi K, Tsukamoto M, Gotoh M, Saitoh N, Kawasugi K. Resistance to activated protein C in systemic lupus erythematosus with antiphospholipid antibodies. Eur J Haematol 1994;53:188.

  40. Matsuda J, Gotoh M, Gohchi K, Kawasugi K, Tsukamoto M, Saitoh N. Resistance to activated protein C activity of an anti-B2-glycoprotein I antibody in the presence of B2-glycoprotein I. Br J Haematol 1995;90:204-206.

  41. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta-2 glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87:4120-4124.

  42. Petraiuola W, Bovill E, Hoak J. The lupus anticoagulant does not inhibit the release of prostacyclin from human endothelial cells. Thromb Haemost 1987;58:390 (Abstract).

  43. Pötzsch B, Kawamura H, Preissner KT, Schmidt M, Seelig C, Müller-Berghaus G. Acquired protein C dysfunction but not decreased activity of thrombomodulin is a possible marker of thrombophilia in patients with lupus anticoagulant. J Lab Clin Med 1995;125:56.

  44. Ruiz-Argüelles A, Ruiz-Argüelles GJ, Presno-Bernal M et al. Protein C (PC) dysfunction in systemic lupus erythematosus (SLE) and in primary antiphospholipid syndrome (PAPS). Relationship to antiphospholipid antibodies. Arthritis Rheum 1988;31:S67 (Abstract).

  45. Ruiz-Argüelles A, Pérez-Romano B, Anglés-Cano E, et al. Mecanismos de la trombofilia lúpica: Investigación de anticuerpos séricos contra el activador tisular del plasminógeno (t-PA) en pacientes con lupus eritematoso generalizado (LEG). Sangre 1992; 37: 95-101.

  46. Ruiz-Argüelles A, Vázquez-Prado J, Delezé M, et al. Presence of serum antibodies to coagulation protein C in patients with systemic lupus erythematosus is not associated with antigenic or functional protein C deficiences. Am J Hematol 1993;44:58-59.

  47. Ruiz-Argüelles A, Anglés-Cano E, Pérez-Romano B, Ruiz-Argüelles GJ, Delezé M, Alarcón-Segovia D, Gaussem P. Serum antibodies to distinct epitopes of the tissue-type plasminogen activator (t-PA) patients with systemic lupus erythematosus. Am J Hematol 1995;49:109.

  48. Ruiz-Argüelles GJ, Ruiz-Argüelles A, Presno-Bernal M et al. Coagulation protein C deficiency in systemic lupus erythematosus and in primary antiphospholipid syndrome. Blood 1988;72:374ª (Abstract).

  49. Ruiz-Argüelles GJ, Ruiz-Argüelles A, Delezé M, Alarcón-Segovia D. Acquired protein C deficiency in a patient with primary anti-phospholipid syndrome. Relationship to reactivity of the anticardiolipin antibody with thrombomodulin. J Rheumatol 1989;16:381-383.

  50. Ruiz-Argüelles GJ, Ruiz-Argüelles A, Lobato-Mendizábal E et al. Disturbances in the tissue plasminogen activator/plasminogen activator inhibitor (TPA/PAI) system in systemic lupus erythematosus. Am J Hematol 1991; 37: 9-13.

  51. Ruiz-Argüelles GJ, Delezé M, Alarcón-Segovia D. Correctly diagnosing a newly characterized syndrome. Am J.Hematol 1991;37:135

  52. Ruiz-Argüelles GJ, Ruiz-Argüelles A, Alarcón-Segovia D et al. Natural anticoagulants in systemic lupus erythematosus. Deficiency of protein S bound to C4bp associates with recent history of venous tromboses, antiphospholipid antibodies and the antiphospholipid syndrome. J Rheumatol 1991;18: 552-558.

  53. Ruiz-Argüelles GJ, Ruiz-Argüelles A, Alarcón-Segovia D. Possible mechanisms on the relationship of antiphospholipid antibodies and deficiencies of the proteins C/S system. Br J Haematol 1991;77: 568-569.

  54. Ruiz-Argüelles GJ, Ruiz-Argüelles A. El síndrome antifosfolípido. En: López-Borrasca A, Arocha-Pinango CL, Campos-Guerra C, Parreira A, Pavlovsky S, Ruiz-Argüelles GJ, San Miguel JF, editores. Enciclopedia Iberoamericana de Hematología. Salamanca, España: Ediciones Universidad de Salamanca, 1992.p. III. 637-III. 645.

  55. Ruiz-Argüelles GJ, Ruiz-Argüelles A, Pérez-Romano B, Alarcón-Segovia D. Protein S deficiency associated to anti-protein S antibodies in a patient with mixed connective-tissue disease and its reversal by danazol. Acta Haematol 1993;89:206-208.

  56. Ruiz-Argüelles A, Anglés-Cano E, Pérez-Romano B, Ruiz-Argüelles GJ, Delezé M, Alarcón-Segovia D, Gaussem P. Serum antibodies to distinct epitopes of the tissue-type plasminogen activator (t-PA) in patients with systemic lupus erythematosus. Am J Hematol 1995;49:109-114.

  57. Ruiz-Argüelles GJ.: Resistencia a la proteína C activada como causa de trombofilia. Rev Invest Clin Mex 1996; 48:223-229.

  58. Ruiz-Argüelles GJ, Garcés-Eisele J, Alarcón-Segovia D, Ruiz-Argüelles A. Activated protein C resistance phenotype and genotype in primary antiphospholipid syndrome. Blood Coagul Fibrinolysis 1996;7:344-348.

  59. Ruiz-Argüellles GJ. Contribuciones mexicanas al conocimiento de las alteraciones trombogénicas en el síndrome de anticuerpos anti-fosfolípido. Rev Iberoam Hemost Tromb 1997: 10:69-71.

  60. Ruiz-Argüelles GJ, Guzmán-Ramos J, Flores-Flores J, Garay-Martínez J.: Refractory hiccough heralding transverse myelitis in the primary antiphospholipid syndrome. Lupus 1998;7:49-50.

  61. Ruiz-Argüelles GJ. Trombofilia. En Ruiz-Argüelles GJ, editor. Fundamentos de hematología. Editorial Médica Panamericana, Ciudad de México 1998. p. 332-342.

  62. Ruiz-Argüelles GJ. The activated protein C resistance phenotype of the antiphospholipid syndrome may follow a relapsing course. Clin Appl Thromb Hemost 1998;4:277-279.

  63. Ruiz-Argüelles GJ, González-Estrada S, Garcés-Eisele J, Ruiz-Argüelles A. Primary thrombophilia in Mexico: a prospective study. Am J Hematol 1999;60:1-5.

  64. Ruiz-Argüelles GJ, Garcés-Eisele J, Reyes-Núñez V, Ramírez-Cisneros F. Primary thrombophilia in México II: Factor V G1691A (Leiden), prothrombin G20210A and methylenetetrahydrofolate reductase C677T polymorphism in thrombophilic Mexican mestizos. Am J Hematol 2001;66:28-31.

  65. Ruiz-Argüelles GJ, Garcés-Eisele J, Ruiz-Delgado GJ, Alarcón-Segovia D. The G20210A polymorphism in the 3´-untranslated region of the prothrombin gene in Mexican mestizo patients with primary antiphospholipid syndrome. Clin Appl Thrombosis/Hemostasis 1999; 5:158-160.

  66. Ruiz-Argüelles GJ, López-Martínez B, Estrada E, Ruiz-Delgado GJ, Alarcón-Segovia D.: Are there “attenuated” forms of the Evans syndrome? Hematology 2002 (In press).

  67. Ruiz-Argüelles GJ, López-Martínez B, Cruz-Cruz D, Reyes-Aulis MB. Primary thrombophilia in Mexico III. A prospective study of the sticky platelet syndrome. Clin Appl Thromb Hemost 2002, (In prens).

  68. Sánchez-Medal L, Lisker R. Circulating anticoagulants in disseminated lupus erythematosus. Brit J Haemat 1959;284-289.

  69. Triplett DA. Laboratory diagnosis of lupus anticoagulants. Semin Thrombos Hemost 1990;16:182-192.

  70. Tsakiris DA, Settas L, Makris PE, Marbet GA. Lupus anticoagulant-antiphospholipid antibodies and thrombophilia. Relation to protein C-protein S-thrombomodulin. J Rheumatol 1990;17:785-789.

  71. Vlachoyiannopoulos PG, Tsiakou E, Chalevelaski G et al. Antiphospholipid syndrome : Clinical and therapeutic aspects. Lupus 1994;3: 91-96.

  72. Walker ID, Hickman GM, Stevenson C, McCall F. High prevalence of aPC resistance in the presence of antiphospholipids. Br J Haematol 1994 86(Suppl 1):2.

  73. González-Llaven J, García-Chavez J. Neoplasías malignas y alteraciones de la coagulación. Enciclopedia Iberoamericana de Hematología. Vol. III. Salamanca, España, Ediciones. Universidad de Salamanca; 1992. p. 537

  74. Dufty M, Reilly DO, Sullivan C, O’Higgins S, et al. Urokinase plasminogen activator, a new independent prognostic marker in breast cancer. Cancer Res 1990;50:6827-6829.

  75. Hajjar KA. Changing concepts in fibrínolysis. Curr Opin Hematol 1995; 2:345-50.

  76. Astrap T. Fibrinolysis; past and present, a reflection of fifty years. Thromb Hemos 1991:17:161-174.

  77. Hajjar KA. Cellular receptor in the regulation of plasmin generation. Thromb Hemost 1995;74:294-301.

  78. Del Vecchio S, Stopelli P, Carriero M, et.al. Human urokinase receptor concentation in malignant and benign brest tumor by in vitro quantitative autoradiography comparison with urokinase level. Cancer Res 1993;53:3198-3206.

  79. Janicke F, Schmitt M, Ulm K,et.al. Urokinase type plasminogen activator antigen and early relapse in brest cancer. Lancet 1989;2:1049.

  80. Foekens J. Schmitt M, Peters H, et al. Prognostic value of urokinase type plasminogen activator in 671 primary brest cancer patients. Cancer Res 1992;52:6101-6110.

  81. Wiman B. Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease. Thromb Haemost 1995;74;71-7

  82. Clavel C, Chavanel G, Birembaui P. Detection of the plasmin system in human mamary pathology using inmunofluorescence.

  83. Monoll JS, Cesarman GM, Molaughlin MA, et al. Annexin II potential role in the coagulopathy of promyelocytic leukemia. J Invest Med 1995;43:376 A.

  84. Aznavoorian S, Murphy A, Stetler-Stevenson W, et al. Molecular aspects of tumor cell invasion and metastasis. Cancer 1993;71:1368-1378

  85. Takeuchi Y, Nakao A, Harada A, et al. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma immunohistochemical . AM J Gatroenterology 1993;88:1928-1933.

  86. Landau B, Kwaan H, Verrusio, E., Brem s. Elevated levels of urokinase type plasminogen activators and plasminogen activator inhibitor type-1 in malignant human brain tumors. Cancer Res 1994;54:1105-1108.




2020     |     www.medigraphic.com